Biocare Medical, Concord, Calif, and Bethyl Laboratories, Montgomery, Texas, have published a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody, for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human cells.

TIGIT has an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with all the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The usage of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy.

"We're excited for the launch of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been demonstrated to exhibit high sensitivity and specificity based on our internal study," states Jason Ramos, PhD, vice president Reagent Research and Development in Biocare Medical. "We think our newest TIGIT IVD antibody is going to be a cost-effective IHC solution to the biotech and pharmaceutical research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development."

TIGIT [BLR047F] is a IVD antibody offered in a focus format to encourage titration by end-users in addition to a ready-to-use predilute format. TIGIT [BLR047F] antibody is available for immediate purchase inside the domestic United States and European Union.

For additional information, visit <span style="color: #ff6600;"><a style="color: #ff6600;" href="http://www.bethyl.com/">Bethyl Laboratories</a></span> and <span style="color: #ff6600;"><a style="color: #ff6600;" href="http://www.biocare.net/">Biocare Medical</a>.</span>